


## Formylation of 2-methylpyrimidine-4,6-diol under the conditions of the Vilsmeier-Haack reaction

Aleksandr V. Dambaev<sup>1,\*</sup>, Denis A. Kolesnik<sup>1</sup>, Igor P. Yakovlev<sup>1</sup> and Tamara L. Semakova<sup>1</sup><sup>1</sup>State Federal-Funded Educational Institution of Higher Education «Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Healthcare of the Russian Federation»,  
Department of Organic Chemistry

## INTRODUCTION &amp; AIM



Pyrimidine hydroxy derivatives have a rather wide range of biological activities, while possessing a high drug safety profile [1]. Our attention was drawn to 2-methylpyrimidine-4,6-diol (**1**), the 5-formyl derivative of which potentially possesses antihypertensive activity with a high probability (0.8) according to *in silico* screening data [2].

The Vilsmeier-Haack method was chosen to perform the formylation as the most efficient among the known methods for the introduction of a formyl group into heterocyclic systems [3].


The aim of this work is to study the Vilsmeier-Haack reaction for substrate **1** and to select the optimal solvent for the reaction.

## METHOD

*In silico* bioactivity screening for 4,6-dihydroxy-2-methylpyrimidine-5-carbaldehyde (**2**) was performed using the PASS Online web resource.

The interaction of substrate **1** with Vilsmeier's reagent in a 1:1 ratio gave 4,6-dihydroxy-2-methylpyrimidine-5-carbaldehyde (**2**). The substitution of hydroxyl groups for chlorine observed in reactions with similar substrates did not occur [3] (Sh. 1).

The progress of the synthesis was monitored by thin layer chromatography (TLC). The structure of product **2** was proved by NMR spectroscopy at <sup>1</sup>H and <sup>13</sup>C nuclei and mass spectrometry.



Scheme 1. Interaction of substrate **1** with Vilsmeier's reagent.

## RESULTS &amp; DISCUSSION

Based on the screening data using the web resource PASS Online, product **2** with probability (Probably active) greater than 0.8 is an agonist of I<sup>1</sup>-imidazoline receptors, which determines antihypertensive activity.

Regardless of the solvent used, the reaction of substrate **1** with Vilsmeier's reagent in a 1:1 ratio resulted in the formation of product **2**, which is confirmed by NMR spectroscopy data at the <sup>1</sup>H (Fig. 1) and <sup>13</sup>C nuclei (Fig. 2), as well as by mass spectrometry (Fig. 3).

As a result of this work, the optimal solvent for the above reaction was selected. In DMF medium, product **2** was obtained in the highest practical yield of 61 % in 5 hours (tabl. 1).




Figure 3. Mass spectrum of product **2** (ESI in negative ion mode).




Figure 1. <sup>1</sup>H NMR spectrum of product **2**.




Figure 2. <sup>13</sup>C NMR spectrum of product **2**.

Solvent	Temperature, °C	Synthesis time, h	Yield, %
DMF	79-81	5	61
1,2-dichloroethane	82-84	6	50
benzene	79-81	6	48
o-xylene	99-101	7	49

Table 1. Dependence of reaction parameters on the solvent used.

## CONCLUSION

The reaction of 2-methylpyrimidine-4,6-diol with Vilsmeier's reagent at their equivalent ratio leads to the formation of only 4,6-dihydroxy-2-methylpyrimidine-5-carbaldehyde. Nucleophilic substitution of hydroxyl groups for chlorine does not occur.

The use of DMF as a solvent in the formation of substrate **1** leads to higher practical yield of product **2** and shorter synthesis time compared to benzene, 1,2-dichloroethane and o-xylene.

## REFERENCES

- Samotrueva M. A., et al. "Farmakologicheskaya aktivnost' proizvodnykh pirimidinov." Astrakhanskii meditsinskii zhurnal 10.1 (2015): 12-29.
- PASS Online. Available online: <https://www.way2drug.com/PassOnline/predict.php> (accessed on 2023.11.12)
- A.P. Rajput, P.D. Girase. Review article on Vilsmeier – Haack reaction // Int. J. Pharmac. Chem. Biolog. Sci. 2012. V. 3(1). P. 25-43.
- Ofitserova, E. S., et al. "Formilirovanie 2-(metiltio)pirimidin-4,6-diola v usloviakh reaktsii Vil'smeiera-KHaaka (kratkoe soobshchenie)." Razrabotka i registratsiya lekarstvennykh sredstv (2017): 112-114.